Last reviewed · How we verify
Motivation-Phase Varenicline
Motivation-Phase Varenicline is a marketed drug developed by the VA Office of Research and Development, primarily indicated for smoking cessation. The drug holds a key composition patent expiring in 2028, providing a period of market exclusivity. The primary risk is the lack of revenue data and key trial results, which may limit investor confidence and market adoption.
At a glance
| Generic name | Motivation-Phase Varenicline |
|---|---|
| Also known as | Chantix |
| Sponsor | VA Office of Research and Development |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Varenicline for Smoking Reduction in Veterans Not Ready To Quit (PHASE4)
- Effect of Smoking Cessation on Clinical and Microbiological Outcomes of the Non-surgical Periodontal Therapy (NA)
- Study on the Model of Smoking Cessation Intervention and Service Ability Improvement
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Motivation-Phase Varenicline CI brief — competitive landscape report
- Motivation-Phase Varenicline updates RSS · CI watch RSS
- VA Office of Research and Development portfolio CI